Pancreatic cancer drug trial halted after just two patients
NCT ID NCT05442749
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial aimed to see if the drug niraparib could shrink tumors in people with metastatic pancreatic cancer that has certain gene mutations. Only 2 patients were enrolled before the study was terminated early, so we don't have enough information to know if it works. The drug was taken daily as a pill.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib
What this could lead to
If it had worked, niraparib could have offered a new targeted treatment option for a small group of pancreatic cancer patients with specific genetic mutations.
What could go wrong
The trial was terminated early with only 2 participants, so no meaningful conclusions can be drawn. Niraparib may not be effective for this cancer type, and side effects like liver issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, 38043, France
-
Centre Léon Bérard
Lyon, 69373, France